Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Primary Purpose
Urinary Tract Infections
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Cystoscopic Fluid containing Neosporin G. U. Irrigant
Cystoscopy
Cystoscopic Fluid/Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Urinary Tract Infections
Eligibility Criteria
Inclusion Criteria:
- Adult women at least 18 years of age
- Elective Female Pelvic Medicine and Reconstructive Surgery or Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair that require cystoscopy.
Exclusion Criteria:
- Surgeries that include: intradetrusor Botox, vaginal mesh excision, and fistula repair
- Pregnancy
- History of nephrolithiasis
- Allergy to study medications
- Congenital urogenital anomaly
- Neurogenic bladder
Sites / Locations
- MetroHealth Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Standard Care
Neosporin G. U. Irrigant
Arm Description
Standard cystoscopy with normal saline solution.
Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
Outcomes
Primary Outcome Measures
Urinary Tract Infection
Urinary tract infection defined as positive urinalysis, urine culture, and/or positive lower urinary tract symptoms requiring antibiotic treatment.
Secondary Outcome Measures
Full Information
NCT ID
NCT03099863
First Posted
March 23, 2017
Last Updated
December 1, 2021
Sponsor
MetroHealth Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03099863
Brief Title
Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Official Title
Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Infection: A Randomized Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
June 2020 (Actual)
Study Completion Date
June 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
MetroHealth Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Postoperative urinary tract infections (UTIs) affect 20-30% of patients undergoing elective gynecologic surgery and have a significant socioeconomic impact and cost. Preoperative antibiotics, sterile operating techniques, postoperative antibiotic and non-antibiotic medical therapies have been utilized to attempt to decrease this rate with little improvement. Utilization of an intraoperative antibiotic cystoscopic irrigant may decrease postoperative UTIs. The investigators have designed a prospective randomized controlled study to evaluate the effectiveness of an antibiotic cystoscopic fluid in preventing postoperative urinary tract infections in women undergoing elective pelvic floor surgery with cystoscopy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
242 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard Care
Arm Type
Placebo Comparator
Arm Description
Standard cystoscopy with normal saline solution.
Arm Title
Neosporin G. U. Irrigant
Arm Type
Active Comparator
Arm Description
Standard cystoscopy with normal saline solution containing Neosporin® G.U. at a 1mL/1000mL concentration.
Intervention Type
Drug
Intervention Name(s)
Cystoscopic Fluid containing Neosporin G. U. Irrigant
Intervention Description
Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
Intervention Type
Procedure
Intervention Name(s)
Cystoscopy
Intervention Description
Diagnostic cystoscopy performed during pelvic floor surgery
Intervention Type
Drug
Intervention Name(s)
Cystoscopic Fluid/Placebo
Intervention Description
Normal saline cystoscopic fluid
Primary Outcome Measure Information:
Title
Urinary Tract Infection
Description
Urinary tract infection defined as positive urinalysis, urine culture, and/or positive lower urinary tract symptoms requiring antibiotic treatment.
Time Frame
4 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adult women at least 18 years of age
Elective Female Pelvic Medicine and Reconstructive Surgery or Gynecologic Minimally Invasive surgeries including hysterectomy, suburethral sling, and pelvic organ prolapse repair that require cystoscopy.
Exclusion Criteria:
Surgeries that include: intradetrusor Botox, vaginal mesh excision, and fistula repair
Pregnancy
History of nephrolithiasis
Allergy to study medications
Congenital urogenital anomaly
Neurogenic bladder
Facility Information:
Facility Name
MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
We'll reach out to this number within 24 hrs